Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

Company Overview

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Key Stats

• Today's Range: $0.03 to $0.11
• 50-Day Range: $0.00 to $0.14
• 52-Week Range: $0.00 to $1.49
• Volume: 650 shs
• Average Volume: 13,970 shs
• Market Capitalization: $4.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ADXS Stock Analysis - Frequently Asked Questions

How have ADXS shares performed this year?

Ayala Pharmaceuticals' stock was trading at $0.6670 on January 1st, 2024. Since then, ADXS stock has decreased by 84.2% and is now trading at $0.1051.
View the best growth stocks for 2024 here.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) posted its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $0.25 million for the quarter.

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX) and

Company Calendar

• Last Earnings: 9/09/2021
• Today: 10/01/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADXS
• CUSIP: N/A
• CIK: 1100397
• Web: www.ayalapharma.com
• Phone: 609-452-9813
• Fax: 609-452-9818
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($7.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-48,070,000.00
• Net Margins: N/A
• Pretax Margin: -399,876.94%
• Return on Equity: N/A
• Return on Assets: -339.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.30
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $3.24 million
• Price / Sales: 1.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.06) per share
• Price / Book: -0.05

Miscellaneous

• Outstanding Shares: 42,633,000
• Free Float: 42,364,000
• Market Cap: $4.48 million
• Optionable: Not Optionable
• Beta: 1.51